HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
EYE on CHINA
Ascletis gains China market rights from Janssen to a clinical stage HIV protease inhibitor
A scletis announced that the company has licensed develop- ment, manufacturing and commercialization rights from Assent R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, including mainland China and Macau. Janssen will retain all rights in the rest of the world and is eligible to receive royalties based on product sales in Greater China.

“This licensing agreement for TMC310911 adds a third drug candidate in late-stage development to the Ascletis pipeline, which aims to provide innovative therapeutics for important medical needs in China,” said Jinzi J. Wu, Ph.D., Ascletis President and Chief Executive Officer. “Based on research to date, we believe that TMC310911 has the potential to offer a new standard-of-care, especially for HIV-infected patients exhibiting multi-drug resistance to current PIs.”

Published research has shown that TMC310911 offers a higher genetic barrier to the development of resistance than any existing HIV PIs. TMC310911 also exhibits broader activity against multi-PI resistant recombinant clinical isolates of HIV than any currently approved PI, including darunavir, the current standard of care. Moreover, three clinical studies completed by Janssen, including a Phase IIa study, showed TMC310911 to have a favorable safety and tolerability profile and demonstrated clinical proof-of-concept in treatment naïve, HIV positive patients.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy